How should I manage insomnia in a 60-year-old patient who has had difficulty sleeping for the past week?

Management of Acute Insomnia in a 60-Year-Old Patient

For a 60-year-old with only one week of sleep difficulty, watchful waiting with sleep hygiene education is the most appropriate initial approach, as transient insomnia typically resolves spontaneously within days to weeks without intervention. 1

Distinguishing Acute from Chronic Insomnia

• Chronic insomnia disorder requires symptoms occurring at least 3 nights per week for 3 months or more; this patient's 1-week duration does not meet diagnostic criteria for chronic insomnia. 1
• Sleep difficulties are typically transient in most adults, and premature pharmacologic or intensive behavioral intervention may medicalize a self-limiting problem. 1
• If insomnia persists beyond 7–10 days despite appropriate sleep hygiene, further evaluation for underlying sleep disorders (sleep apnea, restless legs syndrome, circadian rhythm disorders) or precipitating medical/psychiatric conditions becomes necessary. 2

Immediate Sleep Hygiene Interventions (First Week)

• Establish a consistent wake time every morning (including weekends) and avoid daytime napping, as irregular sleep-wake schedules perpetuate insomnia even in acute cases. 2
• Eliminate caffeine intake for at least 6 hours before bedtime, avoid evening alcohol consumption, and refrain from vigorous exercise within 2 hours of sleep. 2, 3
• Create an optimal sleep environment: cool bedroom temperature (60–67°F), complete darkness or eye mask, minimal noise or white noise machine, and remove all electronic screens from the bedroom. 2, 3
• Use the bed only for sleep and sex; if unable to fall asleep within 20 minutes, leave the bedroom and engage in a quiet, non-stimulating activity until drowsy, then return to bed. 2

When to Escalate Treatment

If Insomnia Persists at 2–4 Weeks: Initiate CBT-I

• Cognitive Behavioral Therapy for Insomnia (CBT-I) becomes the mandatory first-line treatment if sleep difficulty continues beyond 2–4 weeks, as it provides superior long-term efficacy compared to any medication. 1
• CBT-I includes sleep restriction therapy (limiting time in bed to actual sleep time + 30 minutes, minimum 5 hours), stimulus control (strict bed-use rules), cognitive restructuring (challenging catastrophic thoughts about sleep), and relaxation training (progressive muscle relaxation, diaphragmatic breathing). 1, 2
• CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats demonstrate comparable effectiveness. 1, 2

If CBT-I Fails or Is Unavailable: Consider Short-Term Pharmacotherapy

• Pharmacologic treatment should only be added after CBT-I has been attempted or is being delivered concurrently; medication alone without behavioral therapy yields less durable benefit. 1, 2

For Sleep-Onset Insomnia (Difficulty Falling Asleep):

• Zolpidem 10 mg (5 mg if age ≥65 years) reduces sleep-onset latency by approximately 25 minutes; take within 30 minutes of bedtime with at least 7 hours remaining before planned awakening. 2
• Zaleplon 10 mg (5 mg if age ≥65 years) has an ultrashort half-life (~1 hour) and provides rapid sleep initiation with minimal next-day sedation. 2
• Ramelteon 8 mg is a melatonin-receptor agonist with no abuse potential, no DEA scheduling, and no withdrawal symptoms, making it appropriate for patients with substance-use concerns. 2

For Sleep-Maintenance Insomnia (Frequent Nighttime Awakenings):

• Low-dose doxepin 3–6 mg reduces wake after sleep onset by 22–23 minutes, has minimal anticholinergic effects at hypnotic doses, and carries no abuse potential. 2, 3
• Suvorexant 10 mg (orexin-receptor antagonist) reduces wake after sleep onset by 16–28 minutes and has a lower risk of cognitive and psychomotor impairment than benzodiazepine-type agents. 2

For Combined Sleep-Onset and Maintenance Problems:

• Eszopiclone 2–3 mg (1 mg if age ≥65 years) increases total sleep time by 28–57 minutes and produces moderate-to-large improvements in subjective sleep quality. 2

Medications to Explicitly Avoid

• Trazodone yields only a ~10-minute reduction in sleep latency with no improvement in subjective sleep quality; harms outweigh minimal benefits. 1, 2
• Over-the-counter antihistamines (diphenhydramine, doxylamine) lack efficacy data, cause strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation), and develop tolerance within 3–4 days. 1, 2
• Traditional benzodiazepines (lorazepam, clonazepam, diazepam) have long half-lives leading to drug accumulation, prolonged daytime sedation, higher fall and cognitive-impairment risk, and associations with dementia and fractures. 1, 2
• Antipsychotics (quetiapine, olanzapine) have weak evidence for insomnia benefit and significant risks including weight gain, metabolic dysregulation, extrapyramidal symptoms, and increased mortality in elderly patients. 1, 2
• Melatonin supplements produce only a ~9-minute reduction in sleep latency with insufficient supporting evidence for primary insomnia. 2

Safety Monitoring for Hypnotic Medications (If Prescribed)

• FDA labeling indicates hypnotics are intended for short-term use (≤4 weeks); evidence beyond this period is insufficient. 2
• All benzodiazepine-receptor agonists carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur. 2
• Reassess patients after 1–2 weeks to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects (morning sedation, cognitive impairment). 2
• Use the lowest effective dose for the shortest necessary duration; taper gradually when discontinuing to avoid rebound insomnia. 2

Common Pitfalls to Avoid

• Prescribing hypnotic medication for acute insomnia (< 2 weeks duration) medicalizes a self-limiting condition and creates unnecessary dependence risk. 1
• Initiating pharmacotherapy without first implementing or attempting CBT-I violates strong guideline recommendations and results in less durable benefit. 1, 2
• Using adult dosing in patients approaching age 65; age-adjusted dosing (e.g., zolpidem ≤5 mg, eszopiclone ≤2 mg) becomes essential to reduce fall risk. 2, 3
• Continuing hypnotic therapy beyond 4 weeks without periodic reassessment (every 2–4 weeks) contradicts FDA labeling and guideline advice. 2